Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On December 28, 2023, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Vicagrel capsule, which is indicated to treat a range of thrombotic cardiovascular and cerebrovascular diseases, including acute coronary syndrome, ischaemic stroke, and peripheral arterial disease....

Related Keywords

Nanjing ,Jiangsu ,China ,United States ,American ,Jiangsu Vcare ,Eric Zhang ,Jiangsu Vcare Pharmatech Co Ltd ,China Pharmaceutical University ,Drug Administration ,American Chemical Society Journal Of Medicinal Chemistry ,New Drug Application ,American Chemical Society ,Medicinal Chemistry ,Black Box Warning ,Nanjing Biomedical ,